Projects per year
Organization profile
Organisation profile
The research proup HEIM is part of the departement IMMI and centers its activity on the biology and treatment of haematological diseases. This activity is spread over the departments of Clinical Haematology and Stem Cell Transplantation (AZ VUB), Clinical Laboratory of Haematology and Immunology (AZ VUB), Blood Transfusion Centre Jette (Red Cross) and the basic research laboratory HEIM at the faculty of medicine. Following specific subjects are under study: 1. Biology of multiple myeloma and related diseases; 2. Molecular and phenotypic follow-up of B cell malignancies during therapy; 3. Stem cell processing and clinical transplantation; 4. Analysis of phenotype of haemopoietic stem cells in health and disease; 5. Homing of mesenchymal stem cell in bone marrow 5. MHC dysregulation in haematological malignancies; 6. Molecular analysis of antithrombine deficiency.
Fingerprint
Dive into the research topics where Hematology is active. These topic labels come from the works of this organisation's members. Together they form a unique fingerprint.
Network
Recent external collaboration on country level. Dive into details by clicking on the dots or
Profiles
-
Marleen Bakkus
- UZBrussel
- Vrije Universiteit Brussel
- Clinical Biology - UZB Researcher
- Hematology
Person: Researcher
-
Veerle Beckers
- UZBrussel
- Vrije Universiteit Brussel
- Hematology
- Hematology - UZB Physician
Person: Researcher, Physician
-
Ann De Becker
- UZBrussel
- Vrije Universiteit Brussel
- Hematology
- Faculty of Medicine and Pharmacy
- Hematology - UZB Physician
Person: Researcher, PhD, Physician
-
Nathan De Beule
- UZBrussel
- Vrije Universiteit Brussel
- Clinical sciences - Academic
- Hematology - UZB Physician
- Hematology
Person: Researcher, Physician
-
Wouter De Brouwer
- UZBrussel
- Vrije Universiteit Brussel
- Hematology
- Basic (bio-) Medical Sciences - Academic
- Hematology - UZB Physician
- Faculty of Medicine and Pharmacy
Person: Researcher, Physician, PhD, Advanced Master's Programme
Projects
-
FWOTM1002: Development of innovative NANObody-based therapies to eradicate REsidual disease in Multiple Myeloma (acronym: NANOREMM)
1/10/20 → 30/09/23
Project: Fundamental
-
FWOTM900: Modulating epigenetic mechanisms to enhance cancer immunotherapy.
Breckpot, K., De Beck, L. & Maes, K.
1/10/18 → 30/09/22
Project: Fundamental
-
OZR3286: Bilateral cooperation within the framework of a joint doctoral project: Bench Fee for Joint PhD VUB-UGent, Vlummens Philip
13/02/18 → 31/12/22
Project: Fundamental
-
SRP48: Strategic Research Programme: Cancer Cell Targeting in Myeloma and Melanoma (MyMe)
Thielemans, K., Vanderkerken, K. & Breckpot, K.
1/11/17 → 31/10/22
Project: Fundamental
Research output
-
Antithrombin p.Thr147Ala: The First Founder Mutation in People of African Origin Responsible for Inherited Antithrombin Deficiency
Orlando, C., de la Morena-Barrio, B., Pareyn, I., Vanhoorelbeke, K., Martínez-Martínez, I., Vicente, V., Corral, J., Jochmans, K. & de la Morena-Barrio, M. E., 1 Feb 2021, In : Thrombosis and Haemostasis. 121, 2, p. 182-191 10 p.Research output: Contribution to journal › Article
1 Citation (Scopus) -
A pilot study on the impact of congenital thrombophilia in COVID-19
de la Morena-Barrio, M. E., Bravo-Pérez, C., de la Morena-Barrio, B., Orlando, C., Cifuentes, R., Padilla, J., Miñano, A., Herrero, S., Marcellini, S., Revilla, N., Bernal, E., Gómez-Verdú, J. M., Jochmans, K., Herranz, M. T., Vicente, V., Corral, J. & Lozano, M. L., 2021, In : European Journal of Clinical Investigation. p. e13546Research output: Contribution to journal › Article
-
Combining dual G9a/DNMTs epigenetic inhibition and immunotherapy to treat metastatic melanoma
De Beck, L., Awad, R. M., De Vlaeminck, Y., Basso, V., Casares, N., Verhulst, S., San José-Enériz, E., De Ridder, K., Goyvaerts, C., Maes, K., Vanderkerken, K., Agirre, X., Prosper, F., Lasarte, J. J., Mondino, A. & Breckpot, K., 2021, (Unpublished).Research output: Unpublished contribution to conference › Unpublished abstract
-
Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations
Rosiñol, L., Beksac, M., Zamagni, E., Van de Donk, N. W. C. J., Anderson, K. C., Badros, A., Caers, J., Cavo, M., Dimopoulos, M-A., Dispenzieri, A., Einsele, H., Engelhardt, M., Fernández de Larrea, C., Gahrton, G., Gay, F., Hájek, R., Hungria, V., Jurczyszyn, A., Kröger, N., Kyle, R. A. & 18 others, , 2021, In : British Journal of Haematology.Research output: Contribution to journal › Article
-
G9a/GLP-targeting in MM promotes autophagy-associated apoptosis and boosts proteasome inhibitor mediated cell death
Muylaert, C., De Bruyne, E., Maes, K., Vlummens, P., De Smedt, E., Moreaux, J. & Devin, J., 24 Feb 2021, (Accepted/In press) In : Blood Advances.Research output: Contribution to journal › Article
Activities
-
Targeting of pyrroline-5-carboxylate reductase (PYCR) reduces drug resistance in multiple myeloma in vitro.
Inge Oudaert (Speaker), Eline Menu (Contributor), Kim De Veirman (Contributor)29 Jan 2021 → 30 Jan 2021Activity: Talk or presentation › Talk or presentation at a conference
-
LSM PHD DAY
Margo Willems (Chair), Wout De Mey (Chair), Axelle Cooreman (Organiser), Michiel De Coster (Organiser), Hamide Yildirim (Organiser), Catharina Muylaert (Organiser)31 Mar 2021Activity: Participating in or organising an event › Participation in workshop, seminar
-
Bone marrow microenvironment and MGUS progression (Bari, Italy)
Kim De Veirman (Invited speaker)5 Nov 2020 → 7 Nov 2020Activity: Talk or presentation › Talk or presentation at a conference
-
AXL: A potential therapeutic target to improve chemosensitivity in Multiple Myeloma (BACR Annual Meeting 2020)
Kim De Veirman (Contributor), Niels Vandewalle (Speaker)7 Feb 2020Activity: Talk or presentation › Talk or presentation at a conference
-
Postgraduate course BHS 2019-2021
Ann De Becker (Chair)18 Jan 2020Activity: Participating in or organising an event › Participating in or organizing an event at an external academic organisation